Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 987 Neoplasms 796 Carcinoma, Non-Small-Cell Lung 763 Prostatic Neoplasms 588 Colorectal Neoplasms 484 Lung Neoplasms 468 Neoplasm Metastasis 413 Multiple Myeloma 382 Leukemia, Myeloid, Acute 377 Ovarian Neoplasms 316 Pancreatic Neoplasms 297 Melanoma 278 Squamous Cell Carcinoma of Head and Neck 258 Recurrence 244 Carcinoma, Hepatocellular 240 Brain Neoplasms 226 Glioblastoma 217 Triple Negative Breast Neoplasms 204 Carcinoma, Renal Cell 200 Head and Neck Neoplasms 198 Lymphoma 193 Stomach Neoplasms 190 Precursor Cell Lymphoblastic Leukemia-Lymphoma 189 Sarcoma 172 Glioma 171 Uterine Cervical Neoplasms 169 Lymphoma, Non-Hodgkin 169 Endometrial Neoplasms 169 Lymphoma, Large B-Cell, Diffuse 166 Urinary Bladder Neoplasms 160

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × mCRPC × 90 days × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡